Decoding PARP inhibitors: A new hope in treating hereditary cancer
Channel: MHSc Medical Genomics
Date: 05/12/2023

Decoding PARP inhibitors: A new hope in cancer
This webinar is designed to inform on the fundamental aspects of BRCA-associated hereditary cancer and the use of poly ADP ribose polymerase (PARP) inhibitors in treatment.  The video introduces hereditary breast and ovarian cancer (HBOC) syndrome and follows it with a discussion on general patient guidelines when using the PARP inhibitory drug Olaparib (Lynparza).  This science communication material has been conceptualized and created by Kamalika, Nowrin and Shifat, students in the MHSc Medical Genomics program at the University of Toronto. 

Disclaimer: This video is an independent production and is not endorsed or sponsored by any company or industry. This content is not paid for or influenced by any company. Any references to products, services, or organizations are for informational purposes only and should not be considered as endorsements. Viewer discretion is advised.

License: This work is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/    

Resources:
The video has been created using images and graphics from Canva: (https://www.canva.com/) and the audio generated using invideoAI: (https://invideo.io/)
Information on breast cancer:
Cancer Care Ontario (https://www.cancercareontario.ca/en/types-of-cancer/breast-cancer)
Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/index.htm)
Government of Canada (https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/breast-cancer.html)
GeneReviews (https://www.ncbi.nlm.nih.gov/books/NBK1247/)

PARP inhibitors:
BC Cancer Olaparib 9 (http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Olaparib_monograph.pdf)
Canadian Agency for Drugs and Technologies in Health (CADTH) (https://www.cadth.ca/sites/default/files/DRR/2023/PC0299%20Lynparza%20-%20Confidential%20Draft%20CADTH%20Recommendation%20February%202%2C%202023_For%20Posting.pdf)
Cancer Care Ontario PARP (https://www.cancercareontario.ca/en/system/files_force/olaparib.pdf?download=1)
Cancer Research UK (https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors#:~:text=PARP%20inhibitors%20are%20a%20type,all%20examples%20of%20PARP%20inhibitors.)
Lynparza (Olaparib) (https://www.lynparza.com/)

Clinical trials:
OlympiA Clinical Trial (https://clinicaltrials.gov/study/NCT02032823)
OlympiA Trial publication (https://www.nejm.org/doi/full/10.1056/nejmoa2105215)
SOLO-1 Clinical Trial (https://clinicaltrials.gov/study/NCT01844986)
SOLO-1 Trial publication (https://pubmed.ncbi.nlm.nih.gov/36082969/)